AIT-082; A DRUG FOR TREATMENT OF ALZHEIMER'S DISEASE

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16260
Amount: $478,811.00
Phase: Phase II
Program: SBIR
Awards Year: 1993
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Advanced Immunotherapeutics
2691 Richter Avenue, Suite 105, Irvine, CA, 92714
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Glasky, Alvin J
 Principal Investigator
 (714) 756-2230
Business Contact
 1 R43 AG09911-01
Phone: () -
Research Institution
N/A
Abstract
WE WILL DEVELOP AIT-082 FOR THE TREATMENT OF DEMENTIA DUE TO ALZHEIMER'S DISEASE, STROKE OR AGING. IN PHASE I, WE PLAN TO COMPLETE THE PRECLINICAL STUDIES NEEDED TO SUBMIT AN INVESTIGATION- AL NEW DRUG (IND) EXEMPTION APPLICATION TO THE FOOD AND DRUG ADMINISTRATION (FDA). SPECIFICALLY, WE WILL: (1) DETERMINE THE PRECLINICAL PHARMACODYNAMICS/ PHARMACOKINETICS OF AIT-082, (2) CONDUCT PRECLINICAL TOXICOLOGICAL TESTING, AND (3) CONDUCT ADDITIONAL PRECLINICAL STUDIES ON THE MECHANISM OF ACTION OF AIT- 082. THE AIM OF PHASE II WILL BE TO FILE AN IND APPLICATION AND TO ESTABLISH THE CLINICAL SAFETY AND EFFICACY OF AIT-082.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government